3Q13 Revenue: Seikagaku

Year in Review Quarterly Review Current & Critical Funding Regulatory Voice of Industry Financials
Take me to BARE BONES! ORTHOKNOW content is posted to these pages in real time. Monthly compilations are available in PDF form. Apr 2019 Issue Mar 2019 Issue Feb 2019 Issue Quarterly Review 3Q13 Revenue: Seikagaku November 6, 2013 (For FY2Q13 ended 9/30/13; notes pertain to 1HFY13) ¥7,758MM (~US $78.6MM), +19% Growth supported by ex-domestic sales of Gel-One injectable for knee osteoarthritis pain In 4Q, Genzyme filed an appeal in the Gel-One patent infringement suit; expecting no impact on sales U.S. SUPARTZ injectable sale-s fell slightly due to reimbursement restrictions, while sales of ARTZ to China continue to develop favorably

Quarterly Review